FLARE THERAPEUTICS PRESENTS PRECLINICAL DATA THAT SHOW POTENTIAL OF NOVEL PPARG INHIBITORS TO TREAT UROTHELIAL CANCER AT 2022 EORTC-NCI-AACR SYMPOSIUM